Reformulated BeneFix®: Efficacy and safety in previously treated patients with moderately severe to severe haemophilia B

Haemophilia

Volumn 13, Issue 3, 2007, Pages 233-243

  Lambert, Thierry ^a   Recht, M ^b   Valentino, L A ^c   Powell, J S ^d   Udata, C ^e   Sullivan, S T ^f   Roth, D A ^f  

^a BICÊTRE HOSPITAL   (France)

^b PHOENIX CHILDREN'S HOSPITAL   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Department of Clinical Pharmacology ^*  (United States)

^f Clinical Research   (United States)

Author keywords

BeneFix; Factor IX; Haemophilia B; Pharmacokinetics

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN; BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; FOLLOW UP; HEMOPHILIA B; HUMAN; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; THROMBOGENICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; CHILD; HEMARTHROSIS; MIDDLE AGED;

ADOLESCENT; ADULT; CHILD; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FACTOR IX; HEMARTHROSIS; HEMOPHILIA B; HEMORRHAGE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS;

EID: 34248532042     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01458.x     Document Type: Article

References (17)

1. UKHCDO. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1-23.
2. Kasper CK. Concentrate safety and efficacy. Haemophilia 2002; 8: 161-5.
3. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
4. Llewelyn CA, Hewitt PE, Knight RSG et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
5. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-9.
6. Wroe SJ, Pal S, Siddique D et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: A case report. Lancet 2006; 368: 2061-7.
7. Ironside JW. Variant Creutzfeldt-Jakob disease: Risk of transmission by blood transfusion and blood therapies. Haemophilia 2006; 12(Suppl. 1): 8-15.
8. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: Safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
9. Ragni MV, Pasi KJ, White GC et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-7.
10. Shapiro A, Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
11. Harrison S, Adamson S, Bonam D et al. The manufacturing process for recombinant factor IX. Semin Hematol 1998; 35(Suppl 2): 4-10.
12. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant g-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-8.
13. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Published online at: http://www.fda.gov/cder/guidance/ index.htm. Accessed December, 2006.
14. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of recombinant factor VIII and IX products. 2000. Published online at: http://www.emea.eu.int/pdfs/human/ bpwg/156199en.pdf. Accessed December, 2006.
15. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
16. Poon M-C. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia 2006; 12(Suppl 4): 61-9.
17. Poon M-C, Lillicrap D, Hensman C, Card R, Scully M-F. Recombinant factor IX recovery and inhibitor safety: A Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.